<h4>Introduction and importance</h4>Brentuximab vedotin (BV) is an anti-CD30 antibody approved for various cancers, including refractory Hodgkin lymphoma (HL), anaplastic large-cell lymphoma (ALCL) among others. This evidence concerns the gene TNFRSF8 and Hodgkins lymphoma.